The effect of synthesis conditions and tunable hydrophilicity on the drug encapsulation capability of PLA and PLGA nanoparticles

Norbert Varga, Viktória Hornok, László Janovák, I. Dékány, Edit Csapó

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Three drugs with different hydrophilicity are encapsulated in poly-lactide (PLA) and Poly(lactide-co-glycolide) (PLGA) drug delivery systems prepared by ring-opening polymerization (ROP). Formation of well-defined core-shell type nanoparticles (NPs) is observed for α-tocopherol (TP) and by systematically altering the hydrophilicity of the drug carrier NPs the entrapment efficiency (EE (%)) can be remarkably controlled. The highest (90%) of EE (%) is obtained for the most lipophilic TP from the applied three drugs in the 75% lactide-containing PLGA75 NPs, which is ca. 69% for PLA NPs. Subsequent to drug loading the detailed characterization of the polymers and the formed NPs was carried out. Precipitation titrations reveal that our PLGAs have narrower weight distribution than the commercially available polymer enabling favorable properties to obtain NPs with better size distribution. It is pointed out that during the synthesis the applied solvent and stabilizing agent play a decisive role in the size distribution and stability of the drug carrier NPs. The Pluronic F127-stabilized NPs have the smallest diameter (ca. 190 nm) with less polydispersity among the applied stabilizing agent in nanoprecipitation.

Original languageEnglish
Pages (from-to)212-218
Number of pages7
JournalColloids and Surfaces B: Biointerfaces
Volume176
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Hydrophilicity
Hydrophobic and Hydrophilic Interactions
Encapsulation
Nanoparticles
drugs
nanoparticles
synthesis
Pharmaceutical Preparations
tocopherol
Drug Carriers
UCON 50-HB-5100
Tocopherols
entrapment
Excipients
Polymers
Polyglactin 910
Poloxamer
polylactic acid-polyglycolic acid copolymer
poly(lactide)
Ring opening polymerization

Keywords

  • Biocompatible polymers
  • Drug encapsulation
  • Ketoprofen
  • PLGA nanoparticles
  • Tocopherol (vitamin E)

ASJC Scopus subject areas

  • Biotechnology
  • Surfaces and Interfaces
  • Physical and Theoretical Chemistry
  • Colloid and Surface Chemistry

Cite this

The effect of synthesis conditions and tunable hydrophilicity on the drug encapsulation capability of PLA and PLGA nanoparticles. / Varga, Norbert; Hornok, Viktória; Janovák, László; Dékány, I.; Csapó, Edit.

In: Colloids and Surfaces B: Biointerfaces, Vol. 176, 01.04.2019, p. 212-218.

Research output: Contribution to journalArticle

@article{d1404ed0873d4588831f194540cf57bf,
title = "The effect of synthesis conditions and tunable hydrophilicity on the drug encapsulation capability of PLA and PLGA nanoparticles",
abstract = "Three drugs with different hydrophilicity are encapsulated in poly-lactide (PLA) and Poly(lactide-co-glycolide) (PLGA) drug delivery systems prepared by ring-opening polymerization (ROP). Formation of well-defined core-shell type nanoparticles (NPs) is observed for α-tocopherol (TP) and by systematically altering the hydrophilicity of the drug carrier NPs the entrapment efficiency (EE ({\%})) can be remarkably controlled. The highest (90{\%}) of EE ({\%}) is obtained for the most lipophilic TP from the applied three drugs in the 75{\%} lactide-containing PLGA75 NPs, which is ca. 69{\%} for PLA NPs. Subsequent to drug loading the detailed characterization of the polymers and the formed NPs was carried out. Precipitation titrations reveal that our PLGAs have narrower weight distribution than the commercially available polymer enabling favorable properties to obtain NPs with better size distribution. It is pointed out that during the synthesis the applied solvent and stabilizing agent play a decisive role in the size distribution and stability of the drug carrier NPs. The Pluronic F127-stabilized NPs have the smallest diameter (ca. 190 nm) with less polydispersity among the applied stabilizing agent in nanoprecipitation.",
keywords = "Biocompatible polymers, Drug encapsulation, Ketoprofen, PLGA nanoparticles, Tocopherol (vitamin E)",
author = "Norbert Varga and Vikt{\'o}ria Hornok and L{\'a}szl{\'o} Janov{\'a}k and I. D{\'e}k{\'a}ny and Edit Csap{\'o}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.colsurfb.2019.01.012",
language = "English",
volume = "176",
pages = "212--218",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",

}

TY - JOUR

T1 - The effect of synthesis conditions and tunable hydrophilicity on the drug encapsulation capability of PLA and PLGA nanoparticles

AU - Varga, Norbert

AU - Hornok, Viktória

AU - Janovák, László

AU - Dékány, I.

AU - Csapó, Edit

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Three drugs with different hydrophilicity are encapsulated in poly-lactide (PLA) and Poly(lactide-co-glycolide) (PLGA) drug delivery systems prepared by ring-opening polymerization (ROP). Formation of well-defined core-shell type nanoparticles (NPs) is observed for α-tocopherol (TP) and by systematically altering the hydrophilicity of the drug carrier NPs the entrapment efficiency (EE (%)) can be remarkably controlled. The highest (90%) of EE (%) is obtained for the most lipophilic TP from the applied three drugs in the 75% lactide-containing PLGA75 NPs, which is ca. 69% for PLA NPs. Subsequent to drug loading the detailed characterization of the polymers and the formed NPs was carried out. Precipitation titrations reveal that our PLGAs have narrower weight distribution than the commercially available polymer enabling favorable properties to obtain NPs with better size distribution. It is pointed out that during the synthesis the applied solvent and stabilizing agent play a decisive role in the size distribution and stability of the drug carrier NPs. The Pluronic F127-stabilized NPs have the smallest diameter (ca. 190 nm) with less polydispersity among the applied stabilizing agent in nanoprecipitation.

AB - Three drugs with different hydrophilicity are encapsulated in poly-lactide (PLA) and Poly(lactide-co-glycolide) (PLGA) drug delivery systems prepared by ring-opening polymerization (ROP). Formation of well-defined core-shell type nanoparticles (NPs) is observed for α-tocopherol (TP) and by systematically altering the hydrophilicity of the drug carrier NPs the entrapment efficiency (EE (%)) can be remarkably controlled. The highest (90%) of EE (%) is obtained for the most lipophilic TP from the applied three drugs in the 75% lactide-containing PLGA75 NPs, which is ca. 69% for PLA NPs. Subsequent to drug loading the detailed characterization of the polymers and the formed NPs was carried out. Precipitation titrations reveal that our PLGAs have narrower weight distribution than the commercially available polymer enabling favorable properties to obtain NPs with better size distribution. It is pointed out that during the synthesis the applied solvent and stabilizing agent play a decisive role in the size distribution and stability of the drug carrier NPs. The Pluronic F127-stabilized NPs have the smallest diameter (ca. 190 nm) with less polydispersity among the applied stabilizing agent in nanoprecipitation.

KW - Biocompatible polymers

KW - Drug encapsulation

KW - Ketoprofen

KW - PLGA nanoparticles

KW - Tocopherol (vitamin E)

UR - http://www.scopus.com/inward/record.url?scp=85059443398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059443398&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2019.01.012

DO - 10.1016/j.colsurfb.2019.01.012

M3 - Article

AN - SCOPUS:85059443398

VL - 176

SP - 212

EP - 218

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

ER -